Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Inclusion Criteria: * Men aged ≥40 years and life expectancy of ≥10 years. * Serum prostate-specific antigen (PSA) ≤15 ng/mL. * Transperineal prostate biopsy within 12 months prior to dosing, with a clinically significant lesion correlating with an mpMRI visible lesion. * Radiological stage T1-T2 N0 Mx/M0 disease. * A visible lesion on mpMRI that is accessible to PRX302 transperineal injection. Exclusion Criteria: * Previous radiation therapy to the pelvis. * Androgen suppression or anti-androgen therapy within the 12 months prior to dosing, for prostate cancer. * Use of a 5-alpha reductase inhibitor within the 3 months prior to dosing. * Evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging. * Inability to tolerate a transrectal ultrasound (TRUS). * Known allergy to latex or gadolinium (Gd). * Previous electroporation, radiofrequency ablation, high-intensity focused ultrasound (HIFU), cryosurgery, thermal or microwave therapy to treat cancer of the prostate. * Unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc. likely to contribute significant artifact to images).